Navigation Links
Atherotech to Exhibit the VAP(R) Cholesterol Test at ACC.09 in Orlando
Date:3/17/2009

Cardio-diagnostic company adds new apoAI measurement and apoB/apoAI ratio to advanced lipid profile for heart disease risk stratification

BIRMINGHAM, Ala., March 17 /PRNewswire/ -- Atherotech, Inc., today announced it will be exhibiting its VAP(R) Cholesterol Test in booth #1263 at ACC.09, the American College of Cardiology (ACC) 58th Annual Scientific Session Exposition. The annual meeting takes place March 29-31, 2009, at the Orange County Convention Center in Orlando, Fla.

Used in more than 100 clinical trials, including the Heredity and Phenotype Intervention (HAPI) Heart Study recently published in Science, the VAP (Vertical Auto Profile) Test is the most accurate cholesterol test available today.

The VAP Test reports 20 separate components of blood cholesterol as opposed to four in a standard test and can identify a far great number of lipid abnormalities (the #1 risk factor for heart disease) than the standard cholesterol test. The test identifies markers for metabolic syndrome, a precursor for diabetes, and is the only single cholesterol test that routinely reports apoAI, apoB, and the apoB/apoAI ratio.

Atherotech recently announced the addition of apolipoprotein AI (apoAI), the main component of protective HDL cholesterol, to its reporting. Several large, prospective studies, including INTERHEART and the AMORIS trials, have clearly shown the apoB/apoAI ratio to be superior to all other cardiovascular disease risk marker ratios.

"ACC 2009 represents an excellent setting in which to convey the unique benefits of advanced cholesterol profiling to medical professionals from around the world," said Atherotech Chief Medical Officer James Ehrlich, M.D.

Atherotech representatives will be available to discuss the VAP Cholesterol Test in booth #1263, and blood draws will be provided to qualified attendees during exhibit hours March 29-31. Because LDL is directly measured, fasting is not required. Test results will be returned via mail after the conference.

The VAP Test provides researchers and medical professionals with direct measurement of LDL, HDL and all relevant subclasses, and includes non-HDL, a highly accurate determination of apoB, and emerging risk factors such as Lp(a), remnants and small dense LDL.

People with a family history or an existing condition of diabetes, high blood pressure or heart disease - or who are already taking cholesterol-lowering medication - are candidates for the comprehensive VAP Test. In addition, those who didn't score within the desirable ranges of the standard cholesterol test (i.e. those with triglycerides > 150, HDL < 40, LDL >130, total cholesterol > 200) should also opt for the more detailed VAP Test.

The VAP Test is available nationwide and is covered by most insurance providers, including Medicare and Medicaid. For more information call 877.901.8510 or visit www.thevaptest.com.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test
2. Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
3. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
4. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
5. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
6. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
7. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
8. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
9. Varian Medical Systems to Exhibit X-ray and CT Technologies for Non-Destructive Testing at the Upcoming ASNT 18th Annual Spring Conference
10. Cadient Groups GEL Interactive Technologies to Launch Immerse(SM) Exhibit 4.0 at EXHIBITOR2009
11. National Ergonomics Conference and Expo Reaches 94% Exhibitor Renewal Rate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group CEO Benito ... the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, Ross received ... cell transplantation for hematologic disorders and the suppression of graft vs. host disease (GVHD) ...
(Date:4/27/2016)... ReportsnReports.com adds 2016 global ... on US, EU, China ... healthcare business intelligence collection of its growing online ... on the Flow Cytometry market spread across 153 ... tables and figures is now available at ...
(Date:4/26/2016)... ... ... The European Patent Office (EPO) today announced that U.S. Biophysicist ... Inventor Award 2016 in the category "Non-European countries." The winners of the 11th edition ... on June 9th. , The human capacity to walk with fluidity is the sum ...
(Date:4/26/2016)... ... ... This unique "Fertility Happy Hour" event will be held at The Saguaro ... lowdown on female fertility and the reproductive technologies that are empowering a new generation ... - The Arizona Center, will give a short presentation and answer questions about ...
Breaking Biology Technology:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):